312 related articles for article (PubMed ID: 35505285)
1. Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.
Gérard AO; Merino D; Van Obberghen EK; Rocher F; Destere A; Lantéri-Minet M; Drici MD
J Headache Pain; 2022 May; 23(1):53. PubMed ID: 35505285
[TBL] [Abstract][Full Text] [Related]
2. Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study.
Woods RH
Pharmacotherapy; 2022 Oct; 42(10):758-767. PubMed ID: 35975575
[TBL] [Abstract][Full Text] [Related]
3. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
Bedrin K; Ailani J; Dougherty C
Headache; 2022 Nov; 62(10):1419-1423. PubMed ID: 36426766
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase
Noseda R; Bedussi F; Gobbi C; Ceschi A; Zecca C
J Headache Pain; 2024 Jan; 25(1):10. PubMed ID: 38243189
[TBL] [Abstract][Full Text] [Related]
5. Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.
Evans RW
Headache; 2019 Sep; 59(8):1360-1364. PubMed ID: 31310337
[TBL] [Abstract][Full Text] [Related]
6. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.
Bunker CB; Reavley C; O'Shaughnessy DJ; Dowd PM
Lancet; 1993 Jul; 342(8863):80-3. PubMed ID: 8100913
[TBL] [Abstract][Full Text] [Related]
7. The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans.
Merino D; Gérard AO; Van Obberghen EK; Destere A; Lanteri-Minet M; Drici MD
Neurotherapeutics; 2023 Sep; 20(5):1305-1315. PubMed ID: 37436579
[TBL] [Abstract][Full Text] [Related]
8. [Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks].
Stepień A; Jagustyn P; Trafny EA; Widerkiewicz K
Neurol Neurochir Pol; 2003; 37(5):1013-23. PubMed ID: 15174248
[TBL] [Abstract][Full Text] [Related]
9. Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators.
Doggrell SA
Expert Opin Investig Drugs; 2001 Jun; 10(6):1131-8. PubMed ID: 11772240
[TBL] [Abstract][Full Text] [Related]
10. Calcium channel blockers for primary Raynaud's phenomenon.
Ennis H; Anderson ME; Wilkinson J; Herrick AL
Cochrane Database Syst Rev; 2014 Jan; (1):CD002069. PubMed ID: 24482037
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
de Vries T; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
[TBL] [Abstract][Full Text] [Related]
12. Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.
Sun W; Li Y; Xia B; Chen J; Liu Y; Pang J; Liu F; Cheng H
Front Pharmacol; 2023; 14():1257282. PubMed ID: 38264523
[No Abstract] [Full Text] [Related]
13. The CGRP Pathway in Migraine as a Viable Target for Therapies.
Edvinsson L
Headache; 2018 May; 58 Suppl 1():33-47. PubMed ID: 29697153
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®.
Noseda R; Bedussi F; Gobbi C; Ceschi A; Zecca C
Cephalalgia; 2023 Apr; 43(4):3331024231158083. PubMed ID: 36855950
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
16. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.
Breen ID; Brumfiel CM; Patel MH; Butterfield RJ; VanderPluym JH; Griffing L; Pittelkow MR; Mangold AR
JAMA Netw Open; 2021 Apr; 4(4):e217934. PubMed ID: 33871613
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.
Noseda R; Bedussi F; Gobbi C; Zecca C; Ceschi A
Cephalalgia; 2021 Jun; 41(7):789-798. PubMed ID: 33435709
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel signal of Raynaud's phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches.
Singh R; Kumar A; Lather V; Sharma R; Pandita D
Expert Opin Drug Saf; 2024 Feb; 23(2):231-238. PubMed ID: 37594041
[TBL] [Abstract][Full Text] [Related]
20. Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine.
Manickam AH; Buture A; Tomkins E; Ruttledge M
Clin Case Rep; 2021 Aug; 9(8):e04625. PubMed ID: 34430000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
